S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
Freshworks gets juiced on its AI customer engagement platform
All the trading advice you’ve ever received boils down to this (Ad)
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
3 tech outperformers adored by analysts
All the trading advice you’ve ever received boils down to this (Ad)
High short interest stocks: this popular trend is re-emerging
Boeing glides past series of setbacks on new flight path
All the trading advice you’ve ever received boils down to this (Ad)
Fed is set to leave interest rates unchanged while facing speculation about eventual rate cuts
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
Freshworks gets juiced on its AI customer engagement platform
All the trading advice you’ve ever received boils down to this (Ad)
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
3 tech outperformers adored by analysts
All the trading advice you’ve ever received boils down to this (Ad)
High short interest stocks: this popular trend is re-emerging
Boeing glides past series of setbacks on new flight path
All the trading advice you’ve ever received boils down to this (Ad)
Fed is set to leave interest rates unchanged while facing speculation about eventual rate cuts
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
Freshworks gets juiced on its AI customer engagement platform
All the trading advice you’ve ever received boils down to this (Ad)
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
3 tech outperformers adored by analysts
All the trading advice you’ve ever received boils down to this (Ad)
High short interest stocks: this popular trend is re-emerging
Boeing glides past series of setbacks on new flight path
All the trading advice you’ve ever received boils down to this (Ad)
Fed is set to leave interest rates unchanged while facing speculation about eventual rate cuts
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
Freshworks gets juiced on its AI customer engagement platform
All the trading advice you’ve ever received boils down to this (Ad)
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
3 tech outperformers adored by analysts
All the trading advice you’ve ever received boils down to this (Ad)
High short interest stocks: this popular trend is re-emerging
Boeing glides past series of setbacks on new flight path
All the trading advice you’ve ever received boils down to this (Ad)
Fed is set to leave interest rates unchanged while facing speculation about eventual rate cuts
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it

Rocket Pharmaceuticals (RCKT) Stock Price, News & Analysis

$25.23
-1.07 (-4.07%)
(As of 12/8/2023 08:57 PM ET)
Compare
Today's Range
$25.22
$26.59
50-Day Range
$16.78
$26.30
52-Week Range
$14.89
$26.61
Volume
1.27 million shs
Average Volume
901,663 shs
Market Capitalization
$2.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.38

Rocket Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
99.7% Upside
$50.38 Price Target
Short Interest
Bearish
10.08% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
0.15mentions of Rocket Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$677,083 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.03) to ($2.70) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.39 out of 5 stars

Medical Sector

182nd out of 942 stocks

Pharmaceutical Preparations Industry

58th out of 424 stocks


RCKT stock logo

About Rocket Pharmaceuticals Stock (NASDAQ:RCKT)

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. The company is headquartered in Cranbury, New Jersey.

RCKT Stock Price History

RCKT Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Trading Down 3.2%
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
See More Headlines
Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
12/11/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/26/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RCKT
Employees
240
Year Founded
2018

Price Target and Rating

Average Stock Price Target
$50.38
High Stock Price Target
$65.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+99.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$-221,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.47 per share

Miscellaneous

Free Float
62,120,000
Market Cap
$2.27 billion
Optionable
Optionable
Beta
1.02

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Gaurav D. Shah M.D. (Age 48)
    CEO & Director
    Comp: $1.05M
  • Ms. Kinnari Patel M.B.A. (Age 44)
    Pharm.D., President & COO
    Comp: $849.93k
  • Mr. John C. Militello CPA (Age 50)
    VP, Senior Controller, Treasurer, Principal Accounting Officer & Interim Principal Financial Officer
    Comp: $501.42k
  • Mr. Mayo Pujols (Age 54)
    Chief Technical Officer & Executive VP
    Comp: $649.71k
  • Mr. Raj Prabhakar M.B.A. (Age 49)
    Senior VP & Chief Business Officer
    Comp: $619.13k
  • Mr. Martin Louis Wilson J.D. (Age 47)
    General Counsel, Chief Compliance Officer & Senior VP
    Comp: $149.95k
  • Kevin Giordano
    Director of Corporate Communications
  • Ms. Isabel Carmona J.D.
    Senior VP & Chief Human Resources Officer
  • Mr. Jonathan Schwartz M.D. (Age 58)
    Chief Gene Therapy Officer & Senior VP of Clinical Development
    Comp: $557.79k
  • Dr. Gayatri R. Rao J.D.
    M.D., Chief Development Officer of LVV & Senior VP














RCKT Stock Analysis - Frequently Asked Questions

Should I buy or sell Rocket Pharmaceuticals stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RCKT shares.
View RCKT analyst ratings
or view top-rated stocks.

What is Rocket Pharmaceuticals' stock price target for 2024?

9 brokerages have issued 12 month target prices for Rocket Pharmaceuticals' stock. Their RCKT share price targets range from $35.00 to $65.00. On average, they predict the company's share price to reach $50.38 in the next year. This suggests a possible upside of 99.7% from the stock's current price.
View analysts price targets for RCKT
or view top-rated stocks among Wall Street analysts.

How have RCKT shares performed in 2023?

Rocket Pharmaceuticals' stock was trading at $19.57 on January 1st, 2023. Since then, RCKT stock has increased by 28.9% and is now trading at $25.23.
View the best growth stocks for 2023 here
.

When is Rocket Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our RCKT earnings forecast
.

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) issued its quarterly earnings results on Monday, November, 6th. The biotechnology company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.06. During the same period in the previous year, the company posted ($0.87) EPS.

What ETFs hold Rocket Pharmaceuticals' stock?
What other stocks do shareholders of Rocket Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA).

Who are Rocket Pharmaceuticals' major shareholders?

Rocket Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (8.90%), Westfield Capital Management Co. LP (4.65%), Avidity Partners Management LP (1.76%), Bamco Inc. NY (1.23%), Assenagon Asset Management S.A. (1.09%) and JPMorgan Chase & Co. (0.85%). Insiders that own company stock include Gaurav Shah, Gotham Makker, John Militello, Jonathan David Schwartz, Kinnari Patel and Rtw Investments, Lp.
View institutional ownership trends
.

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:RCKT) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -